| Literature DB >> 32676395 |
Weipu Mao1,2, Jinbo Xie2, Yuan Wu2, Zonglin Wu1, Keyi Wang2, Heng Shi2, Hui Zhang3, Bo Peng1,2, Jiang Geng2.
Abstract
BACKGROUND: The purpose of our study was to evaluated the cost-effectiveness of two bladder cancer (BCa) urinary diversions: Studer and Bricker.Entities:
Keywords: Bladder cancer urinary diversion (BCa urinary diversion); Bricker; Studer; incremental cost-effectiveness ratio (ICER); quality-adjusted life-year (QALY)
Year: 2020 PMID: 32676395 PMCID: PMC7354334 DOI: 10.21037/tau.2020.03.46
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Baseline characteristics of the study population
| Characteristics | Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|---|
| Studer, n=44 | Bricker, n=40 | P value | Studer, n=20 | Bricker, n=20 | P value | ||
| Age (SD) | 60.7±6.7 | 65.8±7.0 | 0.001 | 62.9±4.2 | 63.5±7.1 | 0.746 | |
| BMI (kg/m2) | 23.62±2.44 | 24.43±2.84 | 0.167 | 23.48±2.18 | 23.84±3.18 | 0.676 | |
| Sex | 0.188 | 1.000 | |||||
| Male | 42 | 35 | 19 | 19 | |||
| Female | 2 | 5 | 1 | 1 | |||
| CCI | 0.039 | 0.429 | |||||
| ≤2 | 38 | 27 | 15 | 17 | |||
| >2 | 6 | 13 | 5 | 3 | |||
| T-stage | 0.950 | 0.984 | |||||
| T1 | 18 | 17 | 7 | 8 | |||
| T2 | 11 | 9 | 6 | 5 | |||
| T3 | 10 | 8 | 4 | 4 | |||
| T4 | 5 | 6 | 3 | 3 | |||
| N-stage | 0.551 | 1.000 | |||||
| N0 | 34 | 33 | 17 | 17 | |||
| N1 | 10 | 7 | 3 | 3 | |||
| M-stage | 0.172 | – | |||||
| M0 | 42 | 40 | 20 | 20 | |||
| M1 | 2 | 0 | 0 | 0 | |||
| Grade | 0.922 | 0.311 | |||||
| Low grade | 2 | 2 | 1 | 0 | |||
| High grade | 42 | 38 | 19 | 20 | |||
| Hospital time (days) | 39.0±9.6 | 29.4±9.4 | <0.001 | 41.7±10.1 | 25.8±8.7 | <0.001 | |
| Survival time (months) | 27.8±15.0 | 25.7±12.8 | 0.501 | 31.33±15.2 | 23.07±13.0 | 0.073 | |
PSM, propensity score matching; BMI, body mass index; CCI, comprehensive complication index.
Comparison of postoperative complications between two groups
| Characteristics | Studer (n=44) | Bricker (n=40) | P value |
|---|---|---|---|
| Difficulty urinating | 1 (2.3%) | – | |
| Ureteral anastomotic stricture | 2 (4.5%) | 2 (5.0%) | |
| Neobladder urethral anastomotic stricture | 1 (2.3%) | – | |
| Urethral tumor recurrence | – | 1 (2.5%) | |
| Incomplete intestinal obstruction | 2 (4.5%) | 3 (7.5%) | |
| Total | 6 (13.6%) | 6 (15.0%) | 0.858 |
Hospital costs for two surgical techniques
| Characteristics | Before PSM ($) | After PSM ($) | |||||
|---|---|---|---|---|---|---|---|
| Studer (n=44) | Bricker (n=40) | P value | Studer (n=20) | Bricker (n=20) | P value | ||
| Overall costs | 7,173.7±1,390.8 | 6,545.2±1,458.4 | 0.047 | 7,192.8±1,357.4 | 6,509.3±1,101.4 | 0.088 | |
| Bed cost | 348.3±85.5 | 262.7±84.3 | <0.001 | 372.1±89.9 | 229.8±77.4 | <0.001 | |
| Comprehensive medical service | 1,043.4±554.0 | 664.2±311.6 | <0.001 | 1,148.0±779.3 | 626.2±246.9 | 0.007 | |
| General medical service cost | 505.0±503.5 | 293.5±132.6 | 0.012 | 634.6±712.7 | 259.0±82.2 | 0.025 | |
| General treatment operation cast | 335.1±154.5 | 203.0±155.5 | <0.001 | 324.4±159.6 | 193.9±128.8 | 0.007 | |
| Nursing care | 157.6±67.8 | 124.1±63.9 | 0.023 | 145.0±62.7 | 130.0±61.9 | 0.449 | |
| Other costs | 45.8±33.6 | 43.6±26.8 | 0.748 | 43.9±30.9 | 43.2±27.7 | 0.946 | |
| Diagnosis costs | 1,425.0±404.5 | 1,454.2±594.6 | 0.792 | 1,454.5±340.8 | 1,399.7±513.7 | 0.693 | |
| Pathological diagnosis cost | 440.8±150.9 | 446.6±178.8 | 0.871 | 466.1±145.0 | 488.0±217.9 | 0.710 | |
| Laboratory diagnostic cost | 767.8±273.1 | 769.6±435.6 | 0.982 | 781.0±235.4 | 690.5±311.2 | 0.306 | |
| Imaging diagnosis cost | 118.5±90.3 | 134.2±85.5 | 0.415 | 116.3±74.2 | 137.9±86.7 | 0.402 | |
| Clinical diagnosis project cost | 97.9±54.0 | 103.7±68.8 | 0.668 | 91.0±45.5 | 83.3±36.0 | 0.555 | |
| Surgical treatment costs | 1,757.3±300.5 | 1,674.1±303.1 | 0.210 | 1,788.9±308.2 | 1,692.2±291.3 | 0.314 | |
| Anesthesia | 327.7±82.2 | 344.7±101.2 | 0.401 | 355.2±83.0 | 337.7±80.5 | 0.503 | |
| Surgery | 1,430.3±269.9 | 1,329.4±247.1 | 0.079 | 1,435.2±271.5 | 1,354.5±228.1 | 0.315 | |
| Drugs | 1,214.1±550.8 | 917.6±633.4 | 0.024 | 1,287.8±662.3 | 841.6±500.2 | 0.021 | |
| Surgical equipment and medical materials | 1,401.6±674.2 | 1,286.8±463.2 | 0.370 | 1,260.1±328.6 | 1,343.4±523.0 | 0.753 | |
| Other treatment | 375.4±179.7 | 471.3±172.0 | 0.015 | 406.2±183.2 | 5,28.9±177.1 | 0.038 | |
PSM, propensity score matching.
ICER between Studer and Bricker groups
| Characteristics | Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|---|
| Studer (n=44) | Bricker (n=40) | P value | Studer (n=20) | Bricker (n=20) | P value | ||
| QALY | 0.85±0.09 | 0.60±0.08 | <0.001 | 0.84±0.10 | 0.61±0.07 | <0.001 | |
| Cost/QALY | $8,535.6±2,027.6 | $11,158.2±2,944.9 | 0.001 | $8,694.7±2,160.4 | $10,815.5±2,361.0 | 0.001 | |
| ICER | $2,514.0 | $2,971.7 | |||||
PSM, propensity score matching; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.